$PULM

Monteverde & Associates PC says it is investigating merger-related claims involving Pulmatrix (PULM) and Eos SenolyTix, Simulations Plus (SLP) and Altaris affiliates, Olin (OLN) and Huntsman (HUN). It cites expected ownership and deal terms, including $18.50 per SLP share cash and Huntsman receiving 0.5476 OLN shares. Shareholder votes are scheduled for Aug. 25, 2026.

Pulmatrix, Inc. has announced a definitive merger agreement to acquire Eos SENOLYTIX, Inc. in a $19 million deal. The combined entity will operate as Eos SENOLYTIX, Inc., trading on Nasdaq under "EOSX," and will focus on developing peptide therapies for aging-related diseases, particularly sarcopenia, through Eos’s MitoXcel platform. The transaction, which includes concurrent private financings, is subject to stockholder approval and regulatory requirements and is expected to close in mid-2026.

Pulmatrix ( NASDAQ:PULM ) , a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025.